Alteogen obtains patent for antibody-drug conjugate platform for ovarian cancer



Alteogen said on Tuesday it has filed a national patent for an improved antibody used in ALT-Q5, an ovarian cancer treatment, based on the NexMab antibody-drug conjugate (ADC) technology used to develop bio beet ADCs.

Alteogen said Tuesday it has filed a national patent for an improved antibody used in its ALT-Q5 ovarian cancer treatment using NexMab antibody-drug conjugate (ADC) technology.

The antibody inhibits activity by binding to a protein known as the alpha folate receptor (FOLR1) found on the surface of tumor cells in ovarian cancer and plays a key role in the development of therapy ADC against cancer. ALT-Q5 is a modified antibody that helps ADC therapy against ovarian cancer more easily target the tumor cell surface with better antigen binding by enhancing the binding of the previously used antibody.

The technology allows specific binding to FOLR1, which is widely distributed on the surface of various cancer cells. Thus, it could be used to develop anticancer therapies other than ADC for ovarian cancer.

The company filed for a patent in the United States, Europe, China, Japan and Canada in 2020, and recently decided to acquire the same rights in Korea. In addition, Alteogen confirmed the superior anticancer efficacy of its ADC drug against ovarian cancer compared to existing therapies and presented the results of related studies in 2018.

Ovarian cancer is one of the top 10 cancers in women and has the highest death rate. According to Global Data, a market research company, the global ovarian cancer treatment market is expected to reach $ 6.8 billion in 2028.

Bristol Myers Squibb, a global pharmaceutical company, recently signed a $ 3.1 billion contract with Eisai to jointly develop an ADC treatment called MORAb-202, an ADC targeting the alpha folate receptor, and the two companies are leading a phase 1/2 clinical trials in the United States, “said an Alteogen official.” The enhanced binding to FOLR1 increases the possibility of developing ADC therapy for ovarian cancer, and the drug could be developed to treat other cancers, because FOLR1 is also widely distributed on the surface of other cancer cells. “

The company has also transferred its human hyaluronidase technology to three global pharmaceutical companies to develop an anticancer drug for subcutaneous injection since 2019.


Leave A Reply

Your email address will not be published.